Dong-A licenses Zydena to Meiji Seika

Published: 2011-12-21 06:57:00

Updated: 2011-12-21 06:57:00

Dong-A Pharmaceutical Co. Monday announced the signing of an licensing-out agreement with Meiji Seika Pharma, granting Meiji exclusive rights to develop and commercialize Dong-A’s phosphodiesterase-5 inhibitor Zydena (udenafil) for urological indications, with an initial focus on benign prostatic...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK